Farxiga Label Updates 2020 to 2026: A Complete FDA Regulatory Timeline for Dapagliflozin

How Farxiga Went from a Diabetes Drug to a Cardio-Renal Therapy

Dapagliflozin received its first FDA approval on January 8, 2014, as an adjunct to diet and exercise for glycemic control in adults with type 2 diabetes mellitus [1]. The drug entered a market already occupied by canagliflozin (Invokana), and its initial label was narrow: glucose lowering, nothing more. That changed rapidly after 2018, when cardiovascular outcome trials began reporting results that repositioned the entire SGLT2 inhibitor class.

Between 2020 and 2023, the FDA granted three supplemental new drug application (sNDA) approvals for Farxiga, each one expanding the drug's clinical reach beyond diabetes [2][3][4]. No other SGLT2 inhibitor accumulated indications at the same pace. By 2024, dapagliflozin carried the broadest label in its class, covering type 2 diabetes, heart failure regardless of ejection fraction, and chronic kidney disease with or without diabetes.

The regulatory trajectory of Farxiga offers a case study in how post-approval trial programs can redefine a drug's clinical identity within a single decade.

May 2020: Heart Failure with Reduced Ejection Fraction

The first major label expansion arrived on May 5, 2020, when the FDA approved dapagliflozin 10 mg to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure and reduced ejection fraction (HFrEF, NYHA class II, IV) [2]. This was the first time any SGLT2 inhibitor received an HF indication independent of diabetes status.

The approval rested on DAPA-HF (Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure), a randomized, double-blind trial that enrolled 4,744 patients with LVEF ≤40% and NYHA class II, IV symptoms [5]. The primary composite endpoint of worsening heart failure or cardiovascular death occurred in 16.3% of patients receiving dapagliflozin versus 21.2% on placebo (HR 0.74; 95% CI 0.65 to 0.85; P<0.001). The benefit was consistent regardless of baseline diabetes status. Among the 55% of participants without diabetes, the hazard ratio was 0.73 [5].

Dr. John McMurray, lead DAPA-HF investigator and professor at the University of Glasgow, stated: "The magnitude of benefit was similar in patients with and without type 2 diabetes, suggesting that the mechanism of action in heart failure is independent of glucose lowering" [5].

The FDA review was completed under priority review designation, with the label specifying that dapagliflozin's heart failure benefit was additive to background guideline-directed medical therapy including ACE inhibitors, ARBs, beta-blockers, and mineralocorticoid receptor antagonists [2].

April 2021: Chronic Kidney Disease

Eleven months later, on April 30, 2021, the FDA approved dapagliflozin to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, and hospitalization for heart failure in adults with chronic kidney disease at risk of progression [3]. The label did not require a diabetes diagnosis, making Farxiga the first SGLT2 inhibitor approved for CKD in patients both with and without type 2 diabetes.

The supporting trial, DAPA-CKD, randomized 4,304 participants with an eGFR of 25 to 75 mL/min/1.73 m² and a urinary albumin-to-creatinine ratio of 200 to 5,000 mg/g [6]. The primary composite endpoint (sustained ≥50% eGFR decline, ESKD, or renal/CV death) occurred in 9.2% of the dapagliflozin group versus 14.5% of the placebo group (HR 0.61; 95% CI 0.51 to 0.72; P<0.001) [6]. The trial was stopped early at a pre-specified interim analysis for overwhelming efficacy. That early termination is rare for a kidney trial. It signaled an effect size larger than most nephrologists anticipated.

A notable prescribing information change accompanied this approval: the eGFR threshold for initiating dapagliflozin in CKD was set at ≥25 mL/min/1.73 m², lower than the glycemic-indication threshold of ≥45 mL/min/1.73 m² that had appeared on earlier labels [3]. This reflected the trial's enrollment criteria and the observation that renal protective effects persisted even at severely reduced kidney function.

The 2022 KDIGO Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease subsequently recommended SGLT2 inhibitors as first-line therapy for patients with type 2 diabetes and CKD with eGFR ≥20 mL/min/1.73 m², citing both DAPA-CKD and CREDENCE data [7].

May 2023: Heart Failure Across the Ejection Fraction Spectrum

The third indication came on May 26, 2023, when the FDA expanded the heart failure indication to include patients with heart failure regardless of ejection fraction, not only HFrEF [4]. This update was based on the DELIVER trial (Dapagliflozin Evaluation to Improve the Lives of Patients with Preserved Ejection Fraction Heart Failure), which enrolled 6,263 patients with LVEF >40% and structural heart disease [8].

DELIVER demonstrated a 18% relative risk reduction in the composite of cardiovascular death or worsening heart failure (HR 0.82; 95% CI 0.73 to 0.92; P<0.001) [8]. The effect was consistent across subgroups defined by ejection fraction, including patients with LVEF ≥60%. Dapagliflozin became the first pharmacotherapy to show a statistically significant benefit in heart failure with preserved ejection fraction (HFpEF), a condition sometimes described as cardiology's "largest unmet need."

The 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure already included a Class 2a recommendation for SGLT2 inhibitors in HFpEF prior to the full DELIVER publication, based on preliminary data [9]. The 2023 label update aligned the FDA-approved indication with guideline recommendations.

With this change, the Farxiga label no longer distinguished between HFrEF and HFpEF. The prescribing information simply listed "heart failure" as the approved indication for reducing cardiovascular death and hospitalization.

Safety Label Revisions: DKA, Fournier's Gangrene, and UTIs

The 2020 to 2026 period also included several safety-focused labeling changes, most of them applied across the SGLT2 inhibitor class rather than to dapagliflozin specifically.

Diabetic Ketoacidosis (DKA). In 2020, the FDA reinforced a class-wide warning about euglycemic DKA associated with SGLT2 inhibitors [10]. The updated label required prescribers to assess patients for ketoacidosis if they present with nausea, vomiting, abdominal pain, or malaise, even when blood glucose levels are below 250 mg/dL. Post-market surveillance through the FDA Adverse Event Reporting System (FAERS) had identified over 200 confirmed DKA cases with SGLT2 inhibitors between 2013 and 2020, many occurring peri-operatively or during acute illness. The revised label recommended temporarily discontinuing Farxiga at least 3 days before scheduled surgery [10].

Fournier's Gangrene (Necrotizing Fasciitis of the Perineum). Originally added to all SGLT2 inhibitor labels in August 2018, this warning has been retained on every subsequent revision through 2026 [11]. The FDA identified 55 unique cases of Fournier's gangrene with SGLT2 inhibitors between March 2013 and January 2019, compared to 19 cases across all other antidiabetic drug classes combined during the same period. While rare, the condition carries high morbidity.

Urinary Tract Infections. The Farxiga label has consistently listed serious UTIs including urosepsis and pyelonephritis as warnings and precautions. A 2020 label revision clarified that patients with a history of recurrent UTIs should be monitored and that treatment discontinuation should be considered if a serious UTI develops [1].

Amputations. Unlike the canagliflozin (Invokana) label, which carried a boxed warning for lower-limb amputation from 2017 to 2020, the dapagliflozin label has never included an amputation warning [12]. The DAPA-HF and DAPA-CKD datasets showed no signal for increased amputation risk with dapagliflozin.

Post-Market Surveillance and FDA Sentinel Findings

The FDA's Sentinel System, a distributed data network that monitors the safety of regulated medical products using electronic health records and claims data from over 100 million patients, has conducted ongoing active surveillance of SGLT2 inhibitors since 2017 [13].

Published Sentinel analyses through 2024 have examined rates of DKA, acute kidney injury, bone fracture, and lower-limb amputation across SGLT2 inhibitor users. For dapagliflozin specifically, Sentinel data showed a DKA incidence rate of approximately 0.6 to 1.0 events per 1,000 person-years, consistent with the rate observed in clinical trials [13]. No new safety signals emerged that required additional label modifications beyond those already implemented.

The European Medicines Agency (EMA) conducted a parallel review through its European Public Assessment Report (EPAR) process. The EMA approved matching indication expansions for heart failure (November 2020) and CKD (August 2021), with safety language closely mirroring the FDA's updated prescribing information [14].

Dr. David Cherney, nephrologist at the University of Toronto and contributor to multiple SGLT2 inhibitor trial programs, noted in a 2023 commentary: "The regulatory convergence between the FDA and EMA on SGLT2 inhibitor indications reflects the strength and consistency of the trial data across populations and geographies" [15].

What Changed in the Prescribing Information Between 2020 and 2026

The cumulative effect of these label revisions transformed the Farxiga prescribing information document. The original 2014 label was 28 pages. The 2024 revision exceeds 40 pages and includes three distinct indication sections (type 2 diabetes, heart failure, and CKD), each with its own dosing, clinical trial, and patient selection information.

Key prescribing changes across the six-year period include:

• Dosing for heart failure and CKD: 10 mg once daily, with no titration required, regardless of diabetes status [2][3][4].
• eGFR initiation thresholds: For glycemic control, do not initiate if eGFR is <45 mL/min/1.73 m². For CKD, the threshold is ≥25 mL/min/1.73 m². For heart failure, no eGFR threshold is specified [3][4].
• Discontinuation guidance for CKD: Once initiated, dapagliflozin may be continued even if eGFR falls below 25 mL/min/1.73 m², and should be discontinued upon initiation of dialysis [3].
• Pregnancy category: The label warns against use during the second and third trimesters based on animal data showing adverse renal developmental effects. No adequate human pregnancy data are available [1].

These changes reflect a shift from viewing dapagliflozin as a glucose-lowering agent with renal dosing restrictions to a cardio-renal protective therapy with broad eligibility.

How the Farxiga Label Compares to Other SGLT2 Inhibitors

As of early 2026, three SGLT2 inhibitors carry FDA-approved cardiovascular or renal indications beyond type 2 diabetes.

Empagliflozin (Jardiance) received its HFrEF indication in 2022 and a CKD indication in 2023, trailing dapagliflozin by approximately two years in both categories [16]. Canagliflozin (Invokana) holds a diabetic kidney disease indication (2019) but has not received a heart failure indication independent of diabetes. No other SGLT2 inhibitor matches dapagliflozin's breadth of approved indications across heart failure (all EF ranges), CKD (with or without diabetes), and type 2 diabetes.

The 2022 AHA/ACC/HFSA heart failure guideline assigned a Class 1 (Level of Evidence A) recommendation for SGLT2 inhibitors in HFrEF, applicable to both dapagliflozin and empagliflozin [9]. For HFpEF, SGLT2 inhibitors received a Class 2a recommendation, with DELIVER providing the primary evidence base for dapagliflozin.

What Prescribers Should Monitor Going Forward

AstraZeneca has ongoing post-marketing commitments to the FDA, including long-term cardiovascular safety data collection and pediatric study requirements [1]. The 2025 to 2026 period has not produced new indication expansions, but several areas remain under active investigation: dapagliflozin in acute heart failure (DAPA-ACT-HF), post-myocardial infarction heart failure prevention, and type 1 diabetes (an indication the FDA declined in 2019 due to DKA risk concerns).

Prescribers writing dapagliflozin for the CKD or heart failure indications should document the specific approved indication in the medical record, as formulary coverage and prior authorization requirements often differ by indication. Monitor serum creatinine, potassium, and volume status at baseline and within 2 weeks of initiation. Counsel patients on the signs of ketoacidosis, including nausea and abdominal pain with or without hyperglycemia, and instruct them to hold the medication during acute illness or before surgical procedures [10].